Clinical Trial Update: Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON) [Phase 3]

View source ↗

Summary

A Phase 3 trial of idebenone for chronic vision loss due to Leber's hereditary optic neuropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leber Hereditary Optic Neuropathy

Drugs mentioned

• Idebenone (idebenone)

Snippet

Sponsor: Santhera Pharmaceuticals | Conditions: Leber's Hereditary Optic Neuropathy | Phase 3 | Status: WITHDRAWN